Mesoblast

Overview
Price performance
Financials
Research
Thematics

Edison Investment Research is terminating coverage on Mesoblast. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Latest Insights

Healthcare |
edison tv

09.02.22

Mesoblast: Edison Open House Healthcare 2022

Healthcare |
Update

15.03.21

Mesoblast — A significant impact on back pain

Healthcare |
edison tv

03.02.21

Mesoblast – Edison Open House interview

Healthcare |
Update

30.11.20

Mesoblast — Novartis licenses ARDS program

Visit Website

Sector

Healthcare

Balance Sheet

Forecast net cash (US$m)

16.5

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
%	1M	3M	12M
Actual	36.8	(12.3)	(53.5)
Relative	27.6	(7.6)	(50.0)
52 week high/low	A$2.0/A$0.6

Financials

Previously published reports can still be accessed via our website.

Y/E Jun	Revenue (US$m)	EBITDA (US$m)	PBT (US$m)	EPS (fd) (c)	P/E (x)	P/CF (x)
2020A	31.6	(64.8)	(79.6)	(13.28)	N/A	N/A
2021A	7.4	(89.3)	(104.3)	(17.09)	N/A	N/A
2022E	8.6	(83.2)	(92.6)	(14.29)	N/A	N/A
2023E	N/A	N/A	N/A	N/A	N/A	N/A

Research

Update

Healthcare

07.06.17

Mesoblast — Confident management

Update

Healthcare

05.04.17

Mesoblast — Funding to deliver key data in 2017

Healthcare

Update

07.11.17

Mesoblast — Waiting for readouts

Update

Healthcare

28.02.17

Mesoblast — Update 28 February 2017

Update

Healthcare

21.09.16

Mesoblast — Update 21 September 2016

Outlook

Healthcare

08.07.16

Mesoblast — Update 8 July 2016

Update

Healthcare

11.05.16

Mesoblast — Update 11 May 2016

Update

Healthcare

18.02.16

Mesoblast — Update 17 February 2016

Update

Healthcare

25.01.16

Mesoblast — Update 24 January 2016

thematic

Healthcare

26.01.23

Machine learning in drug development

thematic

Healthcare

06.01.23

Outlook for 2023: Biotechs remain central to novel drug development

thematic

Healthcare

04.01.23

Oncology ABCs (part four): Blood cancers (AML) – notable innovations

thematic

Healthcare

20.12.22

Cell and gene therapies

thematic

Healthcare

28.11.22

Drug delivery platforms

thematic

Healthcare

07.11.22

Oncology ABCs (part three) – thinking outside the box in women’s cancer

thematic

Healthcare

01.11.22

Neuroscience comeback

thematic

Consumer

05.10.22

IPO apocalypse

thematic

Healthcare

03.10.22

Oncology ABCs (part two) – vaccines: niche no longer

thematic

TMT

10.08.22

ESG, moving beyond the box tick

thematic

Healthcare

01.07.22

Oncology ABCs (part one) – a small-cap biopharma prospectus series

thematic

Healthcare

26.04.22

Cannabinoid manufacturing – Innovative approaches to the production of cannabinoids

thematic

Healthcare

10.11.21

Artificial intelligence in drug discovery

thematic

Healthcare

27.07.21

Biosynthesis – Taking the cannabinoid market to new heights

thematic

Healthcare

01.02.21

Confidence renewed as new COVID-19 vaccines demonstrate protection against emergent strains and efficacy with a single-dose regimen

thematic

Healthcare

30.10.19

Edison Exhibits- antibiotic development

thematic

Healthcare

17.07.19

The next wave in AMD

thematic

Healthcare

18.06.19

The A-B-T of biosimilars- Explaining contemporary life science issues

thematic

Healthcare

10.06.19

Cannabinoid Therapies- The coming retail wave

thematic

Healthcare

22.05.19

Cannabinoid Therapies- Therapeutics turning a corner

thematic

Healthcare

08.04.19

Trial outcomes and value – Explaining contemporary clinical trial issues

thematic

Healthcare

04.03.19

Drug pricing – Market access and reimbursement

thematic

Healthcare

29.01.19

The diagnostics sector

thematic

Healthcare

21.06.17

ASCO 2017

thematic

Consumer

11.11.14

Deutsche Börse Eigenkapitalforum 2014 Research Guide

thematic

Healthcare

05.03.14

Edison healthcare quarterly: A boost for allergy immunotherapy

thematic

Energy & Resources

04.03.14

ASX Spotlight Conference – London, 6 March 2014

thematic

Energy & Resources

01.03.13

ASX Small to Mid Caps Conference – London, 7 March 2013

thematic

Healthcare

07.12.12

Edison healthcare quarterly: Boom times for US biotech

thematic

Healthcare

30.08.12

Edison healthcare quarterly: Crisis? What crisis?

thematic

Healthcare

28.05.12

Equities

Equities by Sector

Sectors

Investment Strategy

Latest

Equity strategy and market outlook – March 2024

Equity strategy and market outlook – February 2024

Equity strategy and market outlook – January 2024

Thematics

Latest

Listed private equity – Performing a balancing act

ConsumerWatch – At least someone loves me

MediaWatch – Rinse and repeat

Audiovisual

Latest

IP Group – executive interview

Take on Trusts – March 2024

Oakley Capital Investments – executive interview

About Edison

About Edison

Careers

Mesoblast (AU: MSB)

Latest Insights

Mesoblast: Edison Open House Healthcare 2022

Mesoblast — A significant impact on back pain

Mesoblast – Edison Open House interview

Mesoblast — Novartis licenses ARDS program

Sector

Balance Sheet

Share Price Performance

Financials

Research

Mesoblast — Confident management

Mesoblast — Funding to deliver key data in 2017

Mesoblast — Waiting for readouts

Mesoblast — Update 28 February 2017

Mesoblast — Update 21 September 2016

Mesoblast — Update 8 July 2016

Mesoblast — Update 11 May 2016

Mesoblast — Update 17 February 2016

Mesoblast — Update 24 January 2016

Machine learning in drug development

Outlook for 2023: Biotechs remain central to novel drug development

Oncology ABCs (part four): Blood cancers (AML) – notable innovations

Cell and gene therapies

Drug delivery platforms

Oncology ABCs (part three) – thinking outside the box in women’s cancer

Neuroscience comeback

IPO apocalypse

Oncology ABCs (part two) – vaccines: niche no longer

ESG, moving beyond the box tick

Oncology ABCs (part one) – a small-cap biopharma prospectus series

Cannabinoid manufacturing – Innovative approaches to the production of cannabinoids

Artificial intelligence in drug discovery

Biosynthesis – Taking the cannabinoid market to new heights

Confidence renewed as new COVID-19 vaccines demonstrate protection against emergent strains and efficacy with a single-dose regimen

Edison Exhibits- antibiotic development

The next wave in AMD

The A-B-T of biosimilars- Explaining contemporary life science issues

Cannabinoid Therapies- The coming retail wave

Cannabinoid Therapies- Therapeutics turning a corner

Trial outcomes and value – Explaining contemporary clinical trial issues

Drug pricing – Market access and reimbursement

The diagnostics sector

ASCO 2017

Deutsche Börse Eigenkapitalforum 2014 Research Guide

Edison healthcare quarterly: A boost for allergy immunotherapy

ASX Spotlight Conference – London, 6 March 2014

ASX Small to Mid Caps Conference – London, 7 March 2013

Edison healthcare quarterly: Boom times for US biotech

Edison healthcare quarterly: Crisis? What crisis?

Edison healthcare quarterly: How to please some of the people some of the time